Drug intelligence / Profile preview

meteserin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Meteserin is an oral small molecule GLP-1 receptor agonist that was reportedly developed by Metsera for the treatment of obesity. According to provided context, the drug was part of a portfolio acquired by Pfizer in late 2025 or early 2026 to strengthen its obesity franchise. As a GLP-1 receptor agonist, meteserin is designed to mimic the action of the glucagon-like peptide-1 hormone, which regulates appetite and blood sugar levels, thereby promoting weight loss. It was noted to be in Phase 2 clinical development at the time of the acquisition.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on meteserin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on meteserin.

Explore the full profile